6.48
+0.305(+4.94%)
Currency In USD
| Previous Close | 6.17 |
| Open | 6.29 |
| Day High | 6.49 |
| Day Low | 6.19 |
| 52-Week High | 11 |
| 52-Week Low | 3.71 |
| Volume | 240,444 |
| Average Volume | 462,214 |
| Market Cap | 114.36M |
| PE | -1.88 |
| EPS | -3.44 |
| Moving Average 50 Days | 4.95 |
| Moving Average 200 Days | 5.3 |
| Change | 0.31 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $129.5 as of December 04, 2025 at a share price of $6.475. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $908.13 as of December 04, 2025 at a share price of $6.475.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
GlobeNewswire Inc.
Nov 25, 2025 12:05 PM GMT
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 03, 2025 12:05 PM GMT
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
GlobeNewswire Inc.
Oct 30, 2025 11:05 AM GMT
Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill volume (7x) and pill count (2x) from pre-trial phosphate binder therapyLOS ALTOS, Calif